AU2020387399A1 - Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies - Google Patents

Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies Download PDF

Info

Publication number
AU2020387399A1
AU2020387399A1 AU2020387399A AU2020387399A AU2020387399A1 AU 2020387399 A1 AU2020387399 A1 AU 2020387399A1 AU 2020387399 A AU2020387399 A AU 2020387399A AU 2020387399 A AU2020387399 A AU 2020387399A AU 2020387399 A1 AU2020387399 A1 AU 2020387399A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020387399A
Other languages
English (en)
Inventor
Christine Morel COQUERY
Jonathon Andrew KLUFT
William Thomas SYMONDS III
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovant Sciences GmbH
Original Assignee
Immunovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovant Sciences GmbH filed Critical Immunovant Sciences GmbH
Publication of AU2020387399A1 publication Critical patent/AU2020387399A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020387399A 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies Abandoned AU2020387399A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
US62/937,395 2019-11-19
PCT/US2020/061028 WO2021101975A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Publications (1)

Publication Number Publication Date
AU2020387399A1 true AU2020387399A1 (en) 2022-05-19

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020387399A Abandoned AU2020387399A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies

Country Status (11)

Country Link
US (1) US20230049011A1 (https=)
EP (1) EP4061486A1 (https=)
JP (1) JP7722991B2 (https=)
KR (1) KR20220100880A (https=)
CN (1) CN114728180A (https=)
AU (1) AU2020387399A1 (https=)
CA (1) CA3157797A1 (https=)
IL (1) IL292889A (https=)
MX (1) MX2022005862A (https=)
TW (1) TW202132346A (https=)
WO (1) WO2021101975A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250136699A1 (en) * 2021-08-13 2025-05-01 Jiangsu Biojetay Biotechnology Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
US20260078188A1 (en) * 2022-09-06 2026-03-19 Immunovant Sciences Gmbh Methods of treating graves’ disease using anti-fcrn antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3137504T3 (fi) 2014-04-30 2023-08-07 Hanall Biopharma Co Ltd Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
ES2956662T3 (es) * 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
CA3032415A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies

Also Published As

Publication number Publication date
IL292889A (en) 2022-07-01
JP7722991B2 (ja) 2025-08-13
US20230049011A1 (en) 2023-02-16
EP4061486A1 (en) 2022-09-28
CN114728180A (zh) 2022-07-08
WO2021101975A1 (en) 2021-05-27
JP2023502398A (ja) 2023-01-24
MX2022005862A (es) 2022-06-23
TW202132346A (zh) 2021-09-01
CA3157797A1 (en) 2021-05-27
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
JP7489978B2 (ja) 抗ＦｃＲｎ抗体を用いたグレーブス眼症の治療方法
EP3137504B1 (en) Antibody binding to fcrn for treating autoimmune diseases
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
US20260078189A1 (en) Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
JP7722991B2 (ja) 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法
US20260078188A1 (en) Methods of treating graves’ disease using anti-fcrn antibodies
HK40068854A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
HK40121539A (zh) 使用抗fcrn抗体治疗慢性炎性脱髓鞘性多发性神经病的方法
HK40124168A (zh) 使用抗fcrn抗体治疗格雷夫斯病的方法
HK40058301B (zh) 使用抗fcrn抗体治疗格雷夫斯眼病的方法
HK40058301A (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period